NASDAQ:CNST

Constellation Pharmaceuticals Stock Forecast, Price & News

$22.50

-0.31 (-1.36 %)

(As of 04/9/2021 12:00 AM ET)

Add

Compare

Today's Range

$22.34

Now: $22.50▼

$23.17

50-Day Range

$22.81

MA: $27.32▼

$36.84

52-Week Range

$17.00

Now: $22.50▼

$50.90

Volume255,738 shs

Average Volume464,423 shs

Market Capitalization$1.08 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.8

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CNST

Previous Symbol

CUSIP21036U206

CIK29806

Webwww.constellationpharma.com

Phone617-714-0555

Employees154

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.05

Current Ratio15.81

Quick Ratio15.81

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$8.23 per share

Price / Book2.73

Profitability

EPS (Most Recent Fiscal Year)($3.04)

Net Income$-85,550,000.00

Net MarginsN/A

Return on Equity-28.88%

Return on Assets-24.98%

Miscellaneous

Outstanding Shares47,857,000

Market Cap$1.08 billion

Next Earnings Date5/5/2021 (Estimated)

OptionableNot Optionable

Headlines

Zacks: Analysts Anticipate Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) to Announce -$0.80 Earnings Per Share
April 10, 2021 | americanbankingnews.com

Constellation Pharmaceuticals (NASDAQ:CNST) Shares Gap Up to $22.81
April 9, 2021 | americanbankingnews.com

Is CNST Stock A Buy or Sell?
April 8, 2021 | finance.yahoo.com

Royal Bank of Canada Reiterates Buy Rating for Constellation Pharmaceuticals (NASDAQ:CNST)
April 7, 2021 | americanbankingnews.com

Constellation Pharmaceuticals (NASDAQ:CNST) Trading 5.4% Higher
April 5, 2021 | americanbankingnews.com

Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) Given Consensus Rating of "Buy" by Brokerages
April 1, 2021 | americanbankingnews.com

Constellation Pharmaceuticals (NASDAQ:CNST) Shares Up 2.9%
March 25, 2021 | americanbankingnews.com

Notable Two Hundred Day Moving Average Cross - CNST
March 19, 2021 | nasdaq.com

Here's Why We're Not Too Worried About Constellation Pharmaceuticals' (NASDAQ:CNST) Cash Burn Situation
February 26, 2021 | finance.yahoo.com

Constellation Pharmaceuticals (CNST) Q4 2020 Earnings Call Transcript
February 25, 2021 | finance.yahoo.com

CNST Crosses Below Key Moving Average Level
February 24, 2021 | nasdaq.com

Why Constellation's Stock is Trading Lower Today
February 24, 2021 | msn.com

Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2020 Financial Results
February 24, 2021 | finance.yahoo.com

Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2020 Results
February 18, 2021 | finance.yahoo.com

Pharma Stock Ideas: Why BMO Is Recommending Regeneron, Constellation
January 25, 2021 | markets.businessinsider.com

CNST Feb 2021 30.000 call
January 19, 2021 | uk.finance.yahoo.com

CNST210115P00025000 (CNST210115P00025000) interactive stock chart – Yahoo Finance
December 23, 2020 | au.finance.yahoo.com

CNST210319C00035000 (CNST210319C00035000) interactive stock chart – Yahoo Finance
December 21, 2020 | in.finance.yahoo.com

CNST Jan 2021 25.000 put
December 21, 2020 | uk.finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.15 out of 5 stars

Medical Sector

942nd out of 2,010 stocks

Pharmaceutical Preparations Industry

447th out of 769 stocks

3.4 Analyst's Opinion

Consensus Rating
Constellation Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $45.29, Constellation Pharmaceuticals has a forecasted upside of 101.3% from its current price of $22.50.
Amount of Analyst Coverage
Constellation Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Constellation Pharmaceuticals has received 118 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Constellation Pharmaceuticals has received 127 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Constellation Pharmaceuticals has received 51.84% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Constellation Pharmaceuticals and other stocks. Vote “Outperform” if you believe CNST will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CNST will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Constellation Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Constellation Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Constellation Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,340,479.00 in company stock.
Percentage Held by Insiders
Only 10.60% of the stock of Constellation Pharmaceuticals is held by insiders.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Constellation Pharmaceuticals are expected to decrease in the coming year, from ($2.77) to ($3.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Constellation Pharmaceuticals is -8.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Constellation Pharmaceuticals is -8.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Constellation Pharmaceuticals has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$22.50

-0.31 (-1.36 %)

(As of 04/9/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CNST News and Ratings via Email

Sign-up to receive the latest news and ratings for CNST and its competitors with MarketBeat's FREE daily newsletter.

Constellation Pharmaceuticals (NASDAQ:CNST) Frequently Asked Questions

Is Constellation Pharmaceuticals a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Constellation Pharmaceuticals stock.
View analyst ratings for Constellation Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Constellation Pharmaceuticals?

Wall Street analysts have given Constellation Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Constellation Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Constellation Pharmaceuticals' next earnings date?

Constellation Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Constellation Pharmaceuticals.

How were Constellation Pharmaceuticals' earnings last quarter?

Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) released its quarterly earnings data on Tuesday, February, 23rd. The company reported ($0.79) EPS for the quarter, missing the Zacks' consensus estimate of ($0.74) by $0.05.
View Constellation Pharmaceuticals' earnings history.

How has Constellation Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Constellation Pharmaceuticals' stock was trading at $32.57 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CNST shares have decreased by 30.9% and is now trading at $22.50.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for CNST?

7 brokerages have issued 12-month target prices for Constellation Pharmaceuticals' shares. Their forecasts range from $20.00 to $75.00. On average, they anticipate Constellation Pharmaceuticals' stock price to reach $45.29 in the next year. This suggests a possible upside of 101.3% from the stock's current price.
View analysts' price targets for Constellation Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Constellation Pharmaceuticals' key executives?

Constellation Pharmaceuticals' management team includes the following people:

Mr. Jigar Raythatha, Pres, CEO & Director
Ms. Emma Reeve, Chief Financial Officer (Age 60, Pay $570.4k)
Dr. Adrian M. Senderowicz M.D., Sr. Advisor (Age 57, Pay $605.9k)
Dr. Danny Reinberg, Co-Founder
Dr. Yang Shi Ph.D., Co-Founder
Dr. David Allis, Co-Founder
Mr. Mohan Bala Ph.D., Chief Operating Officer
Dr. Patrick Trojer Ph.D., Sr. VP & Chief Scientific Officer (Age 48)
Mr. Ronald Aldridge, Sr. Director of Investor Relations (Age 67)
Kia Khaleghpour Ph.D., VP of Investor Relations & Communications

What is Jigar Raythatha's approval rating as Constellation Pharmaceuticals' CEO?

10 employees have rated Constellation Pharmaceuticals CEO Jigar Raythatha on Glassdoor.com. Jigar Raythatha has an approval rating of 100% among Constellation Pharmaceuticals' employees. This puts Jigar Raythatha in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Constellation Pharmaceuticals' key competitors?

Some companies that are related to Constellation Pharmaceuticals include Biohaven Pharmaceutical (BHVN), Hutchison China MediTech (HCM), Emergent BioSolutions (EBS), Arena Pharmaceuticals (ARNA), Turning Point Therapeutics (TPTX), Legend Biotech (LEGN), Hypera (HYPMY), I-Mab (IMAB), Agios Pharmaceuticals (AGIO), ChemoCentryx (CCXI), Nektar Therapeutics (NKTR), PTC Therapeutics (PTCT), Apellis Pharmaceuticals (APLS), InnovAge (INNV) and Insmed (INSM).
View all of CNST's competitors.

What other stocks do shareholders of Constellation Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Applied Materials (AMAT), Inovio Pharmaceuticals (INO), Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and AT&T (T).

When did Constellation Pharmaceuticals IPO?

(CNST) raised $80 million in an initial public offering on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

What is Constellation Pharmaceuticals' stock symbol?

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

How do I buy shares of Constellation Pharmaceuticals?

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Constellation Pharmaceuticals' stock price today?

One share of CNST stock can currently be purchased for approximately $22.50.

How much money does Constellation Pharmaceuticals make?

Constellation Pharmaceuticals has a market capitalization of $1.08 billion. The company earns $-85,550,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.

How many employees does Constellation Pharmaceuticals have?

Constellation Pharmaceuticals employs 154 workers across the globe.

What is Constellation Pharmaceuticals' official website?

The official website for Constellation Pharmaceuticals is www.constellationpharma.com.

Where are Constellation Pharmaceuticals' headquarters?

Constellation Pharmaceuticals is headquartered at 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142.

How can I contact Constellation Pharmaceuticals?

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]

This page was last updated on 4/10/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here